← All Voyager Therapeutics, INC filings

Voyager Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
VYGR
Voyager Therapeutics, INC
10-K: Voyager Therapeutics Reports 2024 Results, Advances Pipeline in Gene Therapy for Neurological Diseases
Voyager Therapeutics' 2024 10-K filing highlights progress in its gene therapy pipeline for neurological diseases, including Alzheimer's and Parkinson's, with key collaborations and upcoming clinical milestones.
NASDAQ
VYGR
Voyager Therapeutics, INC
10-K: Voyager Therapeutics and Novartis Forge Strategic Collaboration in Gene Therapy
Voyager Therapeutics and Novartis have entered into a licensing and collaboration agreement focused on developing gene therapies for spinal muscular atrophy and Huntingtons disease.